PGNY Stock Recent News
PGNY LATEST HEADLINES
Cramer spoke with Progyny CEO Peter Anevski on Thursday.
ELV vs. PGNY: Which Stock Is the Better Value Option?
Progyny Inc (NASDAQ:PGNY) announced that shipments of its fertility medication Menopur have resumed following an industry wide shortage, prompting the company to boost its fourth quarter and full year guidance. During the company's earnings call on November 3, executives said that the assumption was that Menopur would not be available for the remainder of 2022.
Shares of Progyny Inc. PGNY, +0.17% gained 0.4% in premarket trading Monday, after the fertility benefits management company raised is fourth-quarter financial outlook, given the surprising resumption of deliveries fertility drug Menopur. The company raised its guidance ranges for fourth-quarter earnings per share to 2 cents to 3 cents from a per-share loss of 1 cents to EPS of 2 cents, and for revenue to $208.9 million to $213.9 million from $202.4 million to $212.4 million.
ELV vs. PGNY: Which Stock Is the Better Value Option?
NEW YORK, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Credit Suisse 31st Annual Healthcare Conference on Tuesday, November 8, 2022 at 4:25 P.M. Pacific Time, or 7:25 P.M. Eastern Time.
Progyny, Inc. (NASDAQ:PGNY ) Q3 2022 Earnings Conference Call November 3, 2022 4:45 PM ET Company Participants James Hart - VP, IR Peter Anevski - CEO Mark Livingston - CFO Conference Call Participants Anne Samuel - JPMorgan Jailendra Singh - Truist Securities Scott Schoenhaus - KeyBanc Glen Santangelo - Jefferies Sarah James - Barclays Stephanie Davis - SVB Securities Deb Weerasuriya - Berenberg Operator Good afternoon, ladies and gentlemen, and welcome to the Progyny, Inc. Third Quarter 2022 Earnings Call. At this time, all participants have been placed on a listen-only mode and we will open the floor for your questions and comments after the presentation.
Progyny (PGNY) delivered earnings and revenue surprises of 160% and 5.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ELV vs. PGNY: Which Stock Is the Better Value Option?
Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).